Skip to content

Study · Randomized controlled trial · n = 8 · 1998

10 results

MK-677, an orally active growth hormone secretagogue, reverses diet-induced catabolism.

Murphy MG, Plunkett LM, Gertz BJ, He W, Wittreich J, Polvino WM, Clemmons DR

The Journal of clinical endocrinology and metabolism1 Feb 1998Cited by 59 (Europe PMC)

PMID9467534 (opens in a new tab)DOI10.1210/jcem.83.2.4551 (opens in a new tab)PepBankPUB-09467534
Publisher pagePubMedAsk about this study
Jump to 10 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study10

10 results from studies that gave the peptide. 10 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In calorically restricted volunteers, MK‑677 increased daily nitrogen balance compared with placebo.

    In plain wordsIn calorically restricted volunteers, MK‑677 increased daily nitrogen balance compared with placebo.

    Peptide
    MK-677 (ibutamoren)
    Outcome
    IncreaseDaily nitrogen balance
    Study

    n = 8

    Comparator
    Placebo
    Outcome group
    Protein and amino acid metabolism · Metabolic and weight
    Studied dose
    25 mg once daily · oral · 7 daysAs given in this study (human).

    Measurements

    Mean daily nitrogen balance, MK-677
    0.31 g/day
    MK-677 group, second week (diet and study drug)
    Mean daily nitrogen balance, placebo
    −1.48 g/day
    placebo group, second week (diet and study drug)
    Reported +/- uncertainty in mean daily nitrogen balance, MK-677
    0.21 g/day
    MK-677 group, second week (diet and study drug); uncertainty type not stated in this result sentence
    Reported +/- uncertainty in mean daily nitrogen balance, placebo
    0.21 g/day
    placebo group, second week (diet and study drug); uncertainty type not stated in this result sentence
    P value for mean daily nitrogen balance
    < 0.01 unitless
    MK-677 vs. placebo, second week (diet and study drug)

    Source sentences

    Summary
    During the second week (diet and study drug), mean daily nitrogen balance was 0.31 +/- 0.21 g/day in the MK-677 treatment group compared with -1.48 +/- 0.21 g/day in the placebo group (P < 0.01).
    3 context sentences
    Summary · context
    A double-blind, randomized, placebo-controlled, two-period cross-over study was designed to investigate whether MK-677, an orally active nonpeptide mimic of GH-releasing peptide, can reverse diet-induced protein catabolism.
    Summary · context
    Eight healthy volunteers (ages 24-39 yr) were calorically restricted (18 kcal/kg.day) for two 14-day periods.
    Summary · context
    During the last 7 days of each diet period, subjects received either oral MK-677 25 mg or placebo once daily.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In calorically restricted volunteers, MK‑677 improved integrated nitrogen balance compared with placebo.

    In plain wordsIn calorically restricted volunteers, MK‑677 improved integrated nitrogen balance compared with placebo.

    Peptide
    MK-677 (ibutamoren)
    Outcome
    IncreaseIntegrated nitrogen balance
    Study

    n = 8

    Comparator
    Placebo
    Outcome group
    Protein and amino acid metabolism · Metabolic and weight
    Studied dose
    25 mg once daily · oral · 7 daysAs given in this study (human).

    Measurements

    Nitrogen balance AUC day 8-14, MK-677
    2.69 g.day
    MK-677
    Nitrogen balance AUC day 8-14, placebo
    −8.97 g.day
    placebo
    SE of nitrogen balance AUC day 8-14, MK-677
    5 g.day
    MK-677, day 8-14 nitrogen balance response
    Reported +/- uncertainty in nitrogen balance AUC day 8-14, placebo
    5.26 g.day
    placebo, day 8-14 nitrogen balance response
    P value for nitrogen balance AUC day 8-14
    < 0.001 unitless
    MK-677 vs. placebo, day 8-14

    Source sentences

    Summary
    MK-677 improved nitrogen balance integrated over the 7 days of treatment; area under the curve day 8-14 nitrogen balance response was +2.69 +/- 5.0 (SE) for MK-677 and -8.97 +/- 5.26 g.day for placebo (P < 0.001).
    3 context sentences
    Summary · context
    A double-blind, randomized, placebo-controlled, two-period cross-over study was designed to investigate whether MK-677, an orally active nonpeptide mimic of GH-releasing peptide, can reverse diet-induced protein catabolism.
    Summary · context
    Eight healthy volunteers (ages 24-39 yr) were calorically restricted (18 kcal/kg.day) for two 14-day periods.
    Summary · context
    During the last 7 days of each diet period, subjects received either oral MK-677 25 mg or placebo once daily.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In calorically restricted volunteers, MK‑677 increased peak GH after a single dose compared with placebo.

    In plain wordsIn calorically restricted volunteers, MK‑677 increased peak growth hormone after a single dose compared with placebo.

    Peptide
    MK-677 (ibutamoren)
    Outcome
    IncreasePeak GH after single dose
    Study

    n = 8

    Comparator
    Placebo
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    25 mg once daily · oral · 7 daysAs given in this study (human).

    Measurements

    Peak GH response, MK-677
    55.9 micrograms/L
    MK-677, day 1 of treatment (single dose)
    Peak GH, placebo
    ≈ 9 micrograms/L
    placebo, treatment day 1
    Reported +/- uncertainty in peak GH response, MK-677
    31.7 micrograms/L
    MK-677, single dose (day 1 of treatment); uncertainty type not stated

    Source sentences

    Summary
    MK-677 produced a peak GH response of 55.9 +/- 31.7 micrograms/L after single dose (day 1 of treatment) and 22.6 +/- 9.3 micrograms/L after a week of dosing compared with placebo treatment peak GH values of approximately 9 (treatment day 1) and approximately 7 micrograms/L (treatment day 7).
    3 context sentences
    Summary · context
    A double-blind, randomized, placebo-controlled, two-period cross-over study was designed to investigate whether MK-677, an orally active nonpeptide mimic of GH-releasing peptide, can reverse diet-induced protein catabolism.
    Summary · context
    Eight healthy volunteers (ages 24-39 yr) were calorically restricted (18 kcal/kg.day) for two 14-day periods.
    Summary · context
    During the last 7 days of each diet period, subjects received either oral MK-677 25 mg or placebo once daily.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In calorically restricted volunteers, MK‑677 increased peak GH after a week of dosing compared with placebo.

    In plain wordsIn calorically restricted volunteers, MK‑677 increased peak growth hormone after a week of dosing compared with placebo.

    Peptide
    MK-677 (ibutamoren)
    Outcome
    IncreasePeak GH after repeated dosing
    Study

    n = 8

    Comparator
    Placebo
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    25 mg once daily · oral · 7 daysAs given in this study (human).

    Measurements

    Peak GH response, MK-677
    22.6 micrograms/L
    MK-677, after a week of dosing (treatment day 7)
    Peak GH, placebo
    ≈ 7 micrograms/L
    placebo, treatment day 7
    Reported +/- uncertainty in peak GH response, MK-677
    9.3 micrograms/L
    MK-677, after a week of dosing; uncertainty type not stated

    Source sentences

    Summary
    MK-677 produced a peak GH response of 55.9 +/- 31.7 micrograms/L after single dose (day 1 of treatment) and 22.6 +/- 9.3 micrograms/L after a week of dosing compared with placebo treatment peak GH values of approximately 9 (treatment day 1) and approximately 7 micrograms/L (treatment day 7).
    3 context sentences
    Summary · context
    A double-blind, randomized, placebo-controlled, two-period cross-over study was designed to investigate whether MK-677, an orally active nonpeptide mimic of GH-releasing peptide, can reverse diet-induced protein catabolism.
    Summary · context
    Eight healthy volunteers (ages 24-39 yr) were calorically restricted (18 kcal/kg.day) for two 14-day periods.
    Summary · context
    During the last 7 days of each diet period, subjects received either oral MK-677 25 mg or placebo once daily.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In calorically restricted volunteers, MK‑677 increased mean IGF-I concentration compared with placebo.

    In plain wordsIn calorically restricted volunteers, MK‑677 increased IGF-I compared with placebo.

    Peptide
    MK-677 (ibutamoren)
    Outcome
    IncreaseIGF-I concentration
    Study

    n = 8

    Comparator
    Placebo
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    25 mg once daily · oral · 7 daysAs given in this study (human).

    Measurements

    Mean IGF-I, MK-677
    264 ng/mL
    MK-677, mean of last 5 days of treatment
    Mean IGF-I, placebo
    188 ng/mL
    placebo, mean of last 5 days of treatment
    Reported +/- uncertainty in mean IGF-I, MK-677
    31 ng/mL
    MK-677, mean for the last 5 days of treatment; uncertainty type not stated
    Reported +/- uncertainty in mean IGF-I, placebo
    19 ng/mL
    placebo, mean for the last 5 days of treatment; uncertainty type not stated
    P value for mean IGF-I concentration
    < 0.01 unitless
    MK-677 vs. placebo, mean for the last 5 days of treatment

    Source sentences

    Summary
    Mean IGF-I concentration increased significantly during MK-677 to 264 +/- 31 ng/mL (mean for the last 5 days of treatment) compared with 188 +/- 19 ng/mL with placebo (P < 0.01).
    3 context sentences
    Summary · context
    A double-blind, randomized, placebo-controlled, two-period cross-over study was designed to investigate whether MK-677, an orally active nonpeptide mimic of GH-releasing peptide, can reverse diet-induced protein catabolism.
    Summary · context
    Eight healthy volunteers (ages 24-39 yr) were calorically restricted (18 kcal/kg.day) for two 14-day periods.
    Summary · context
    During the last 7 days of each diet period, subjects received either oral MK-677 25 mg or placebo once daily.
  6. 06HumanRandomized controlled trialEfficacy outcome

    In calorically restricted volunteers, IGF binding protein-2 did not differ significantly between MK‑677 and placebo.

    In plain wordsIn calorically restricted volunteers, IGF binding protein-2 did not differ significantly between MK‑677 and placebo.

    Peptide
    MK-677 (ibutamoren)
    Outcome
    No significant changeIGF binding protein-2
    Study

    n = 8

    Comparator
    Placebo
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    25 mg once daily · oral · 7 daysAs given in this study (human).

    Source sentences

    Summary
    No significant difference in IGF binding protein-2 was found between the MK-677 and placebo treatments.
    3 context sentences
    Summary · context
    A double-blind, randomized, placebo-controlled, two-period cross-over study was designed to investigate whether MK-677, an orally active nonpeptide mimic of GH-releasing peptide, can reverse diet-induced protein catabolism.
    Summary · context
    Eight healthy volunteers (ages 24-39 yr) were calorically restricted (18 kcal/kg.day) for two 14-day periods.
    Summary · context
    During the last 7 days of each diet period, subjects received either oral MK-677 25 mg or placebo once daily.
  7. 07HumanRandomized controlled trialEfficacy outcome

    In calorically restricted volunteers, MK‑677 increased IGF binding protein-3 compared with placebo.

    In plain wordsIn calorically restricted volunteers, MK‑677 increased IGF binding protein-3 compared with placebo.

    Peptide
    MK-677 (ibutamoren)
    Outcome
    IncreaseIGF binding protein-3
    Study

    n = 8

    Comparator
    Placebo
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    25 mg once daily · oral · 7 daysAs given in this study (human).

    Measurements

    Mean IGF binding protein-3, MK-677
    3273 ng/mL
    MK-677, mean of last 5 days of treatment
    Mean IGF binding protein-3, placebo
    2604 ng/mL
    placebo, mean of last 5 days of treatment
    SE of mean IGF binding protein-3, MK-677
    330 ng/mL
    MK-677, mean for the last 5 days of treatment
    SE of mean IGF binding protein-3, placebo
    253 ng/mL
    placebo, mean for the last 5 days of treatment
    P value for mean IGF binding protein-3
    < 0.01 unitless
    MK-677 vs. placebo, mean for the last 5 days of treatment

    Source sentences

    Summary
    However, the mean in IGF binding protein-3 for the last 5 days of MK-677 treatment was also significantly increased to 3273 +/- 330 ng/mL (mean +/- SE) compared with placebo 2604 +/- 253 ng/mL (P < 0.01).
    3 context sentences
    Summary · context
    A double-blind, randomized, placebo-controlled, two-period cross-over study was designed to investigate whether MK-677, an orally active nonpeptide mimic of GH-releasing peptide, can reverse diet-induced protein catabolism.
    Summary · context
    Eight healthy volunteers (ages 24-39 yr) were calorically restricted (18 kcal/kg.day) for two 14-day periods.
    Summary · context
    During the last 7 days of each diet period, subjects received either oral MK-677 25 mg or placebo once daily.
  8. 08HumanRandomized controlled trialEfficacy outcome

    In calorically restricted volunteers, cortisol response was not significantly greater with MK‑677 than placebo.

    In plain wordsIn calorically restricted volunteers, cortisol response was not significantly greater with MK‑677 than placebo.

    Peptide
    MK-677 (ibutamoren)
    Outcome
    No significant changeSerum cortisol response
    Study

    n = 8

    Comparator
    Placebo
    Outcome group
    Stress hormones · Endocrine and hormones
    Studied dose
    25 mg once daily · oral · 7 daysAs given in this study (human).

    Source sentences

    Summary
    Neither the serum cortisol nor the PRL response was significantly greater after 7 days of MK-677 dosing compared with 7 days of placebo.
    3 context sentences
    Summary · context
    A double-blind, randomized, placebo-controlled, two-period cross-over study was designed to investigate whether MK-677, an orally active nonpeptide mimic of GH-releasing peptide, can reverse diet-induced protein catabolism.
    Summary · context
    Eight healthy volunteers (ages 24-39 yr) were calorically restricted (18 kcal/kg.day) for two 14-day periods.
    Summary · context
    During the last 7 days of each diet period, subjects received either oral MK-677 25 mg or placebo once daily.
  9. 09HumanRandomized controlled trialEfficacy outcome

    In calorically restricted volunteers, PRL response was not significantly greater with MK‑677 than placebo.

    In plain wordsIn calorically restricted volunteers, prolactin response was not significantly greater with MK‑677 than placebo.

    Peptide
    MK-677 (ibutamoren)
    Outcome
    No significant changePRL response
    Study

    n = 8

    Comparator
    Placebo
    Outcome group
    Pituitary hormones · Endocrine and hormones
    Studied dose
    25 mg once daily · oral · 7 daysAs given in this study (human).

    Source sentences

    Summary
    Neither the serum cortisol nor the PRL response was significantly greater after 7 days of MK-677 dosing compared with 7 days of placebo.
    3 context sentences
    Summary · context
    A double-blind, randomized, placebo-controlled, two-period cross-over study was designed to investigate whether MK-677, an orally active nonpeptide mimic of GH-releasing peptide, can reverse diet-induced protein catabolism.
    Summary · context
    Eight healthy volunteers (ages 24-39 yr) were calorically restricted (18 kcal/kg.day) for two 14-day periods.
    Summary · context
    During the last 7 days of each diet period, subjects received either oral MK-677 25 mg or placebo once daily.
  10. 10HumanRandomized controlled trialSafety outcome

    In calorically restricted volunteers, MK‑677 was generally well tolerated without clinically significant adverse experiences.

    In plain wordsIn calorically restricted volunteers, MK‑677 was generally well tolerated without clinically significant adverse experiences.

    Peptide
    MK-677 (ibutamoren)
    Outcome
    Not applicableClinically significant adverse experiences
    Study

    n = 8

    Outcome group
    Adverse events · Whole body
    Studied dose
    25 mg once daily · oral · 7 daysAs given in this study (human).

    Source sentences

    Summary
    MK-677 (25 mg) was generally well tolerated and without clinically significant adverse experiences.
    3 context sentences
    Summary · context
    A double-blind, randomized, placebo-controlled, two-period cross-over study was designed to investigate whether MK-677, an orally active nonpeptide mimic of GH-releasing peptide, can reverse diet-induced protein catabolism.
    Summary · context
    Eight healthy volunteers (ages 24-39 yr) were calorically restricted (18 kcal/kg.day) for two 14-day periods.
    Summary · context
    During the last 7 days of each diet period, subjects received either oral MK-677 25 mg or placebo once daily.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    14 Oct 2026, 05:02 UTC

    Study results updated

  2. Version 1

    14 Oct 2026, 01:46 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.